Bad News for President Trump

New Post Public Reply Private Reply Replies (1) Message Board
Bhawks
193
Quote:
Bad News for President Trump

https://www.theatlantic.com/politics/archive/...le/558611/

The Comey memos are more revealing than they seem.
Quinta Jurecic and Benjamin Wittes 7:00 AM ET Politics

snip//

If we accept that Comey’s story has been remarkably consistent over time, and has been corroborated, as Comey has also said, by the contemporaneous FBI witnesses to whom he claims to have told about the events in real time—a few points follow.

First, the president will not realistically defeat an obstruction-of-justice charge—whether it arises in a criminal context or, as is more likely, as an allegation he has to contend with in the political realm—by throwing dust in the air about what happened. The effort so far to discredit Comey by declaring him a liar has the small problem, accentuated by the memos, that he is apparently telling the truth.

And one person who certainly knows that he is telling the truth is Robert Mueller, who has access not merely to the memos but to all of the FBI witnesses in whom Comey confided at the time. Don’t imagine for a minute that what Comey said to them differs materially from what he said to the Senate intelligence committee, to the public, or to his file.

It will all be consistent. And to the extent the president’s forces predicate their arguments on contesting Comey’s account of what happened, they will have to do so relying on the word of a man from whom The Washington Post has documented 2,436 false statements since January 20, 2017. The memos highlight vividly what we already knew: that the facts are a loser for the president.

Second, it follows that the president will have to make his defense on obstruction on different grounds: Ultimately, he’s going to have to argue that the conduct Comey is describing is acceptable behavior.

This would be a tricky business under the best of circumstances, because it’s so manifestly not acceptable behavior in a president. The problem for Trump is that he is most unlikely to get to make this argument under anything like the best of circumstances.

Comey’s story may be the pointy end of the spear the president is facing, but it is not the spear itself—just a piece of it. There’s a lot, after all, that Jim Comey doesn’t know, that isn’t in his testimony, that isn’t in his book, and that isn’t in these memos.

The result is that, third, the facts are likely to get worse—maybe much worse—for Trump. Mueller, remember, doesn’t just know Comey knows. He also has access not only to all the FBI documents and witnesses but also to all the White House documents.

He has access as well to all the White House witnesses. He has had all the key White House staff in front of his team. The only one whose story the public has heard so far is Comey. But that does not mean Comey’s story represents a full accounting of the conduct for which Trump will have to answer to Mueller.

Does it seem likely that the picture is going to look better for the president when we see Comey’s story in the context of the accounts of those of other witnesses?

Or that those other witnesses, when faced with possible jail time for lying to the FBI in their own interviews, told stories that will soften public judgment of the president’s behavior?

In his book, writing about his work as U.S. Attorney in the Southern District of New York, Comey describes how prosecutors draw from a “reservoir of trust and credibility” to do their work. His characterization of the importance of trust to a prosecutor’s work also holds for the role of a witness. Whatever you think of Comey’s actions over the course of 2016, the consistency of his accounts of his interactions with Trump adds more water to that well.

Comey didn’t make this point, but a subject of a criminal investigation, when that person is a public figure, also has a reservoir of trust and credibility. Trump and his supporters are defending the president by arguing that Comey, among others, is lying—but making that argument in the absence of any evidence, and while the body of information corroborating Comey’s account only grows, requires drawing down Team Trump’s own reservoir. And the level of that particular reservoir is, at this stage, very, very low.

Mueller is apparently close to done with his obstruction probe and preparing a report of some kind. Some portion of that report is going to hinge on the credibility of James Comey. For those who were in doubt, the memos give powerful reason to expect that this portion of the report will be damning with respect to the president’s conduct.

But, remember, the memos are boring. The question is how much worse things look when new evidence emerges, and it’s all in one place.

You can’t make websites calling everyone a liar.



Quinta Jurecic is the deputy managing editor of Lawfare
.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading